相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。First-line Chemotherapy in Epithelial Ovarian Cancer
Michael A. Bookman
CLINICAL OBSTETRICS AND GYNECOLOGY (2012)
A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer
Marcela G. del Carmen et al.
GYNECOLOGIC ONCOLOGY (2012)
A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites
Nicoletta Colombo et al.
GYNECOLOGIC ONCOLOGY (2012)
Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
Beth Y. Karlan et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Carol Aghajanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study
Walter H. Gotlieb et al.
LANCET ONCOLOGY (2012)
A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
J. J. Biagi et al.
ANNALS OF ONCOLOGY (2011)
The PACOVAR-trial: A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer
Michael Eichbaum et al.
BMC CANCER (2011)
Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer
F. A. Raja et al.
BRITISH JOURNAL OF CANCER (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Combined Weekly Topotecan and Biweekly Bevacizumab in Women With Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer Results of a Phase 2 Study
Kathryn F. McGonigle et al.
CANCER (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers
Kazuya Kudoh et al.
GYNECOLOGIC ONCOLOGY (2011)
Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
Daniela Matei et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer
Robert L. Coleman et al.
LANCET ONCOLOGY (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study
Jean A. Hurteau et al.
GYNECOLOGIC ONCOLOGY (2010)
Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer A Study of the Princess Margaret Hospital Phase II Consortium
Stephen A. Welch et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2010)
Phase II Study of Carboplatin, Paclitaxel, and Bevacizumab With Maintenance Bevacizumab As First-Line Chemotherapy for Advanced Mullerian Tumors
Richard T. Penson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Biomarkers to predict the clinical efficacy of bevacizumab in cancer
Adrian M. Jubb et al.
LANCET ONCOLOGY (2010)
Bevacizumab plus Low-Dose Metronomic Oral Cyclophosphamide in Heavily Pretreated Patients with Recurrent Ovarian Cancer
Alfonso Sanchez-Munoz et al.
ONCOLOGY (2010)
Second complete remission induced by cyclophosphamide plus bevacizumab in two patients with heavily pre-treated ovarian cancer
Alfonso Sanchez-Munoz et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2009)
Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer
J. D. Hurt et al.
GYNECOLOGIC ONCOLOGY (2009)
Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
Ursula A. Matulonis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma
Levi S. Downs et al.
CANCER (2008)
Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer
Debra L. Richardson et al.
GYNECOLOGIC ONCOLOGY (2008)
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia
Halla S. Nimeiri et al.
GYNECOLOGIC ONCOLOGY (2008)
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
Nilofer S. Azad et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and princess Margaret hospital phase II consortia
Agustin A. Garcia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
VEGF-targeted therapy: mechanisms of anti-tumour activity
Lee M. Ellis et al.
NATURE REVIEWS CANCER (2008)
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
Robert A. Burger et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
Stephen A. Cannistra et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
Justin C. Chura et al.
GYNECOLOGIC ONCOLOGY (2007)
A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer
J. P. Micha et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2007)
Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer
BJ Monk et al.
GYNECOLOGIC ONCOLOGY (2005)
分享论文
